Exsure is working on a way to make chemotherapy less toxic, backed by peer-reviewed research

Summary

Exsure is developing a drug-delivery platform intended to make chemotherapy less toxic, and the work is backed by peer-reviewed research and preclinical testing.

Why it matters

Biotech is slow, but a credible research base can de-risk early commercial conversations. The upside is meaningful because better tolerability can improve adoption as well as outcomes.

Founder/operator read

In science-driven startups, publishable evidence and clear translational milestones matter as much as pitch decks. Show the path from lab result to patient impact.

Original source

Read original